Cancer Research Insights & Advancements

Explore updates on our innovative clinical trials, advancements in cancer research, fundraising efforts and the latest developments in oncology.

For media inquiries: media@marycrowley.org

Sort By

LUNG CANCER: A MULTIDISCIPLINARY APPROACH TO DIAGNOSIS AND MANAGEMENT

Immunological Approaches to the Treatment of Lung Cancer (Chapter 24). In: Lung Cancer: A Multidisciplinary Approach to Diagnosis and Management.

IN: PRINCIPLES AND PRACTICE OF LUNG CANCER: THE OFFICIAL REFERENCE TEXT OF THE IASLC

n: Principles and Practice of Lung Cancer: The Official Reference Text of the IASLC, Fourth Edition (Chapter 51).

HEREDITARY INCLUSION BODY MYOPATHY: SINGLE PATIENT RESPONSE TO GNE GENE LIPOPLEX THERAPY

Hereditary Inclusion Body Myopathy: Single Patient Response to GNE Gene Lipoplex Therapy. The Journal of Gene Medicine 2010 May; 12(5):403-412.

HEAD AND NECK CANCER: RESPONSE TO P53-BASED THERAPEUTICS

Head and Neck Cancer: Response to p53-Based Therapeutics. Head and Neck 2011; 33(1):131-134.

AUGMENTATION OF DOCETAXEL ANTI-TUMOR ACTIVITY BY A STATHMIN-SPECIFIC BI-FUNCTIONAL SHRNA

Augmentation of docetaxel anti-tumor activity by a stathmin-specific bi-functional shRNA.

MANUFACTURING AND STABILITY TESTING OF A GNE-LIPOPLEX FOR A CLINICAL TRIAL FOR THE TREATMENT OF HEREDITARY INCLUSION BODY MYOPATHY TYPE

Manufacturing and Stability Testing of a GNE-Lipoplex for a Clinical Trial for the Treatment of Hereditary Inclusion Body Myopathy Type (HIBM).

NANO-FLOW 2D-HPLC MALDI-TOF MS/MS FOR DIFFERENTIALLY EXPRESSED PROTEIN ANALYSIS IN BREAST CANCER PATIENT SAMPLES

Nano-flow 2D-HPLC MALDI-TOF MS/MS for differentially expressed protein analysis in breast cancer patient samples.

ONCOVEXGM-CSF: AN ONCOLYTIC VIRAL IMMUNOTHERAPEUTIC IN MELANOMA

Senzer N, Bedell C, Nemunaitis J: OncoVEXGM-CSF: An Oncolytic Viral Immunotherapeutic in Melanoma. Drugs of the Future 2010; 35(6):449.

PHASE I SAFETY AND PHARMACOKINETIC STUDY OF SYSTEMIC P53 GENE THERAPY (SGT-53)

Phase I Safety and Pharmacokinetic Study of Systemic p53 Gene Therapy (SGT-53) using Immunolipoplexes Targeted by Anti-Transferrin Receptor (TfR) Single Chain Antibody Fragment (scFv):

Pages: 1234567891011121314151617181920212223242526272829

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.

For media inquiries: media@marycrowley.org

Cancer Research Insights & Advancements

Subscribe to Our Newsletter

Connect With Us